Alimetry, a gastrointestinal medtech and digital health start-up, announced today the creation of a new American Medical Association (AMA) Current Procedural Terminology (CPT) III code for Body Surface Gastric Mapping, which will describe its Gastric Alimetry test.
The new CPT III code highlights the growing recognition of Body Surface Gastric mapping and Gastric Alimetry as a significant advance in the diagnosis and management of chronic gastric conditions, including functional dyspepsia, gastroparesis, and chronic nausea and vomiting syndrome. Together, these disorders affect >10% of the US population.
CEO, Greg O’Grady, a Professor of Surgery and co-founder of Alimetry, said: “Obtaining a CPT III code is a key milestone for Alimetry. Gastric Alimetry is emerging as a next-generation test for patients suffering chronic gastric symptoms, with excellent early adoption in over 30 hospitals and clinics. The new AMA code will accelerate our mission to achieve widespread access for US patients suffering from these disabling disorders.”
The CPT III code comes on the back of Alimetry’s 3rd 510k clearance from the US Food and Drug Administration (FDA) in just 2 years for the Gastric Alimetry System. The latest FDA clearance introduced new features to aid in the diagnosis of gut hypersensitivity and common ‘Gut-Brain-Axis’ disorders, which are often linked to mental wellbeing. Chief Medical Officer Professor Chris Andrews stated: “Gastric symptoms can be complex, and are often a diagnostic challenge. Gastric Aimetry combines a wearable sensor with an App- based digital health profiling tool, providing an increasingly powerful feature set that can greatly simplify the diagnostic process. The cloud-based platform also enables us to rapidly learn and improve test performance based on banked data, with an increasing focus on applications in AI.”
In addition to the new CPT Code, Alimetry also announced positive clinical study results, published this month in the American Journal of Gastroenterology. In the study discussion, the authors concluded that “Gastric Alimetry identified 2.7x more specific patient categories than gastric emptying testing [a standard of care test], with limited overlap between each diagnostic modality, offering a valuable new option in the diagnostic work up of patients with chronic gastroduodenal symptoms”. In addition, Gastric Alimetry data was reported to show “improved correlation with symptoms and psychometrics” compared to existing clinical and research tools.
Gastric Alimetry is commercially available in the United States, the UK and New Zealand. The study article can be accessed in this hyperlink